Back to search

Italy· 024732024

BEZALIP*30 cpr rivestite 400 mg rilascio prolungato

A bezafibrate product containing bezafibrato, registered in Italy by AUROBINDO PHARMA ITALIA Srl, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC C10AB02

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedBEZALIP*30 cpr rivestite 400 mg rilas…ATCC10AB02REGISTER NO.024732024PACKS LISTED1CHECKEDJune 4, 2026

Where it is registered

Bezafibrate is registered in 10 of 19 countries.

Countries holding a registration under ATC C10AB02 (bezafibrate), each read from that country’s own register.

  • This record: Italy
  • 6 of them publish a price we can compare per daily dose

Bezafibrate · ATC C10AB02

10 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Italyprice
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bezafibrate costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), the median price runs from $0.29 in France to $1.19 in Switzerland — a ×4.1 gap.

  • Italy: $0.44 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Bezafibrate · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.19
  • ES Spain$0.45
  • IT Italy$0.44
  • FR France$0.29
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Active substance
Bezafibrato
Manufacturer
AUROBINDO PHARMA ITALIA Srl
Country
Italy (IT)
ATC code
C10AB02
ATC class
Bezafibrate
Defined daily dose
0.6 g, O
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    024732024
    BEZALIP*30 cpr rivestite 400 mg rilascio prolungato
    EUR 7.66

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Bezafibrate in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bezafibrate products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Bezalip Retard, Bezastad
  • Belgium · Cedur, Eulitop
  • Cyprus · Lacromid, Zafibral
  • Germany · Bezafibrat Al, Bezafibrat Retard Al
  • Spain · Eulitop, Eulitop Retard
  • Finland · Bezalip
  • France · Befizal, Befizal L.P.
  • United Kingdom (Northern Ireland) · Bezafibrate, Bezafibrate Noumed Life Sciences
  • Hungary · Bezalip
  • Luxembourg · Cedur, Eulitop
  • Netherlands · Bezafibrate Aurobindo
  • Portugal · Bezalip, Bezalip Retard
  • Romania · Bezafibrat Arena
  • Sweden · Bezalip, Bezalip Retard

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0b8245bb-8a6c-4de4-a78b-37763bcc276e
GET /v1/drugs/0b8245bb-8a6c-4de4-a78b-37763bcc276e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 7.66,
  "source": "aifa",
  "currency": "EUR",
  "strength": "BEZAFIBRATO 400MG 30 UNITA' USO ORALE RP",
  "substance": "Bezafibrato",
  "equivalence_group": "EMA",
  "transparency_flag": null
}

See everything about bezafibrate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.